ArticleBMC ophthalmology2026
Therapeutic effect of faricimab in macular telangiectasia type 1 and Coats' disease: case series.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTo report the anatomical and functional outcomes of intravitreal faricimab injection in cases of macular telangiectasia type 1 and Coats’ disease that were refractory to previous treatments.
methodsWe describe four cases of macular telangiectasia type 1 and Coats’ disease with macular edema, which were treated with intravitreal faricimab injection.
resultsFour patients with persistent cystoid macular edema despite prior treatment received intravitreal faricimab injections, and two of them showed anatomical and visual improvement. In case 1, a patient with Coats’ disease achieved improved telangiectatic vessel at macula and visual recovery following eight monthly injections of faricimab, with central macular thickness (CMT) reduced from 645 μm to 217 μm and BCVA improved from 20/30 to 20/25. In case 2, a patient with diabetic retinopathy and suspected macular telangiectasia type 1 showed improvement in CMT (670 μm to 219 μm) and visual acuity (20/63 to 20/40) with resolution of telangiectatic vessel with leakage after four faricimab injections. Case 3 and 4 were chronic and long-standing cases; in case 3, a patient with Coats’ disease demonstrated partial response with reduced macular edema, while in case 4, with a Coats’ disease, showed no response after two faricimab injections.
conclusionsFaricimab may provide therapeutic benefits in cases of macular telangiectasia type 1 and Coats’ diseases unresponsive to previous anti-VEGF agents, potentially due to its dual inhibition of vascular endothelial growth factor-A and angiopoietin-2. However, its efficacy may be limited in patients with chronic phase. Further studies are warranted to assess its role in vascular retinal diseases beyond currently approved indications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.